NO20061767L - Makrosykliske peptider som er aktive mot hepatitt C virus - Google Patents

Makrosykliske peptider som er aktive mot hepatitt C virus

Info

Publication number
NO20061767L
NO20061767L NO20061767A NO20061767A NO20061767L NO 20061767 L NO20061767 L NO 20061767L NO 20061767 A NO20061767 A NO 20061767A NO 20061767 A NO20061767 A NO 20061767A NO 20061767 L NO20061767 L NO 20061767L
Authority
NO
Norway
Prior art keywords
virus
active against
against hepatitis
macrocyclic peptides
peptides active
Prior art date
Application number
NO20061767A
Other languages
English (en)
Norwegian (no)
Inventor
Montse Llinas-Brunet
Jean Rancourt
Teddy Halmos
Murray D Bailey
Elise Ghiro
Punit Bhardwaj
Pasquale Forgione
Nathalie Goudreau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34375541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061767(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20061767L publication Critical patent/NO20061767L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20061767A 2003-09-22 2006-04-21 Makrosykliske peptider som er aktive mot hepatitt C virus NO20061767L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50483903P 2003-09-22 2003-09-22
PCT/CA2004/001658 WO2005028501A1 (fr) 2003-09-22 2004-09-20 Peptides macrocycliques actifs contre le virus de l'hepatite c

Publications (1)

Publication Number Publication Date
NO20061767L true NO20061767L (no) 2006-06-16

Family

ID=34375541

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061767A NO20061767L (no) 2003-09-22 2006-04-21 Makrosykliske peptider som er aktive mot hepatitt C virus

Country Status (22)

Country Link
US (2) US7642235B2 (fr)
EP (1) EP1673385B1 (fr)
JP (2) JP4704342B2 (fr)
KR (1) KR20060094083A (fr)
CN (1) CN1856502A (fr)
AR (1) AR045938A1 (fr)
AT (1) ATE500264T1 (fr)
AU (1) AU2004274051A1 (fr)
BR (1) BRPI0414571A (fr)
CA (1) CA2536182C (fr)
DE (1) DE602004031645D1 (fr)
EA (1) EA200600498A1 (fr)
EC (1) ECSP066448A (fr)
ES (1) ES2361997T3 (fr)
IL (1) IL174403A0 (fr)
MX (1) MXPA06003141A (fr)
NO (1) NO20061767L (fr)
PE (1) PE20050431A1 (fr)
RS (1) RS20060197A (fr)
TW (1) TW200521144A (fr)
UY (1) UY28525A1 (fr)
WO (1) WO2005028501A1 (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129407A0 (en) 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7157424B2 (en) * 2003-04-02 2007-01-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004092203A2 (fr) * 2003-04-10 2004-10-28 Boehringer Ingelheim International, Gmbh Procede de preparation de composes macrocycliques
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CN1791599A (zh) 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7642235B2 (en) * 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1699558B1 (fr) * 2003-12-08 2009-03-11 Boehringer Ingelheim International GmbH Elimination de sous-produit de ruthenium par traitement fluidique supercritique
EP1730167B1 (fr) * 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Peptides macrocycliques actifs contre le virus de l'hepatite c
CA2556917C (fr) * 2004-03-15 2013-07-09 Boehringer Ingelheim International, Gmbh Procede de preparation de composes macrocycliques
CA2568008C (fr) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Processus de preparation d'inhibiteurs de protease hcv acyclique
CA2573346C (fr) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Analogues peptidiques inhibiteurs de l'hepatite c
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
EP1794179A1 (fr) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Réaction de métathèse cyclisante en milieu fluide supercritique
CA2577831A1 (fr) * 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Procede de fabrication d'inhibiteurs de protease hcv macrocycliques
EP2374464A3 (fr) 2004-10-01 2011-10-26 Vertex Pharmaceuticals Incorporated Inhibition de la protéase N3S-NS4A du virus de l'hépatite C
TWI437990B (zh) 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
DE102005002336A1 (de) 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2332963A3 (fr) 2005-03-08 2011-11-16 Boehringer Ingelheim International Gmbh Procédé pour la préparation de composés macrocycliques
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0613962A2 (pt) * 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
BRPI0613933A2 (pt) 2005-07-29 2011-02-22 Medivir Ab inibidores macrocìlicos do vìrus da hepatite c
UA93377C2 (ru) * 2005-07-29 2011-02-10 Тиботек Фармасьютикелз Лтд. Макроциклические ингибиторы вируса гепатита c
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
AU2006274862B2 (en) * 2005-07-29 2012-03-22 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
AR057704A1 (es) * 2005-07-29 2007-12-12 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014925A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
US7666834B2 (en) * 2005-07-29 2010-02-23 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
EP1915378A4 (fr) 2005-08-12 2009-07-22 Boehringer Ingelheim Int Inhibiteurs de polymerase virale
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
ES2364426T3 (es) * 2005-09-09 2011-09-02 Boehringer Ingelheim International Gmbh Proceso de metátesis con cerrado del anillo para la preparación de péptidos macrocíclicos.
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2625419A1 (fr) * 2005-11-03 2007-05-10 Boehringer Ingelheim International Gmbh Procede de fabrication d'anisidines substituees
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007130704A1 (fr) * 2006-01-25 2007-11-15 Boehringer Ingelheim International Gmbh Procede en deux etapes pour preparer des anisidines substituees
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2646229A1 (fr) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Inhibiteurs de protease de l'hepatite c deuteres
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
RU2009109355A (ru) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Ингибиторы вырусной полимеразы
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008106130A2 (fr) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Peptides substitués par une amine tertiaire utiles comme inhibiteurs de la réplication du virus de l'hépatite c
WO2008106058A2 (fr) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérine protéases
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
CA2708150A1 (fr) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Composes a base de tripeptides fluores inhibant la serine protease du vhc
EP2222161A4 (fr) * 2007-12-05 2011-09-28 Enanta Pharm Inc Dérivés de quinoxalinyle
JP5623289B2 (ja) 2007-12-19 2014-11-12 ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010008523A (es) * 2008-02-04 2010-08-31 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa.
CA2713108A1 (fr) 2008-02-07 2009-08-13 Virobay, Inc. Inhibiteurs de la cathepsine b
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
EP2300491B1 (fr) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Inhibiteurs du virus de l hépatite c
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010068760A2 (fr) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. Nouveaux peptides 4-amino-4-oxobutanoyl utiles en tant qu'inhibiteurs de la réplication virale
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
EP2396028A2 (fr) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Polythérapie contre le hcv comprenant de l'interféron pégylé, de la ribavirine et de la telaprevir
CA2753657A1 (fr) 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Procede de preparation de sulfonyle quinoleines
WO2010118078A1 (fr) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
CA2761650C (fr) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Composes macrocycliques comme inhibiteurs du virus de l'hepatite c
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
PT2451438E (pt) * 2009-07-07 2014-03-26 Boehringer Ingelheim Int Composição farmacêutica para um inibidor de protease viral da hepatite c
WO2011017389A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l’hépatite c
DK2477980T3 (en) 2009-09-15 2016-09-12 Taigen Biotechnology Co Ltd HCV protease inhibitors
CN102020698B (zh) * 2009-09-15 2012-08-29 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
WO2011049908A2 (fr) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Composés bismacrocycliques à titre d'inhibiteurs du virus de l'hépatite c
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
JP2013511561A (ja) * 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
RU2012136824A (ru) 2010-01-29 2014-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способы лечения вирусной инфекции гепатита с
KR102132405B1 (ko) * 2010-05-20 2020-07-09 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
WO2011156545A1 (fr) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Modèle dynamique viral pour une polythérapie contre le vhc
WO2012009503A1 (fr) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Composition pharmaceutique au goût agréable comprenant vx-950
KR101990279B1 (ko) 2010-09-21 2019-06-19 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
EP2658859A4 (fr) 2010-12-30 2014-07-30 Enanta Pharm Inc Inhibiteurs macrocycliques de sérine protéase d'hépatite c
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012109646A1 (fr) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Traitement du vhc chez des patients infectés par le vih
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN107964006A (zh) 2012-01-11 2018-04-27 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
RS55592B1 (sr) 2012-10-19 2017-06-30 Bristol Myers Squibb Co 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2970195B1 (fr) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Processus de production de sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139421A (en) 1960-03-14 1964-06-30 Parke Davis & Co Azo compounds and methods for producing same
CA2032559C (fr) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Pentapeptides cycliques antagonistes de l'endotheline
US5721210A (en) 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
WO1994015958A2 (fr) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Inhibiteurs peptidiques de l'adhesion cellulaire
US5830888A (en) 1993-04-16 1998-11-03 Monsanto Company Macrocyclic retroviral protease inhibitors
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
EP0907659A1 (fr) 1996-05-10 1999-04-14 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
IL129407A0 (en) 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
JPH10298151A (ja) 1997-04-30 1998-11-10 Japan Energy Corp Ｃ型肝炎ウイルスプロテアーゼ阻害剤
CA2291778A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
JPH1135478A (ja) 1997-07-17 1999-02-09 Soyaku Gijutsu Kenkyusho:Kk キク科植物の有機抽出物を含有する抗ｃ型肝炎ウイルス剤及びプロテアーゼｎｓ３の特異的阻害剤
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
JPH11127861A (ja) 1997-10-29 1999-05-18 Japan Energy Corp Ｃ型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド
JP3612551B2 (ja) 1997-11-07 2005-01-19 独立行政法人産業技術総合研究所 Ｃ型肝炎ウイルスのｎｓ３プロテアーゼを阻害するｒｎａ分子
CA2260499A1 (fr) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Compositions pharmaceutiques pour le traitement de dommages ischemiques au cerveau
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
AU3376699A (en) 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JPH11292840A (ja) 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
CA2376961A1 (fr) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
EP1206568A2 (fr) 1999-08-30 2002-05-22 K.U. Leuven Research & Development Cible pour des agents antiparasitaires et inhibiteurs de ladite cible
JP2001103993A (ja) 1999-10-05 2001-04-17 Japan Energy Corp 環状ペプチド及びセリンプロテアーゼ阻害剤
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
AU2055301A (en) 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6624290B2 (en) 2000-02-08 2003-09-23 Schering Corporation Azapeptides useful in the treatment of Hepatitis C
JP2003525294A (ja) 2000-02-29 2003-08-26 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害剤
DE60111509T2 (de) 2000-04-03 2006-05-11 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
PL359359A1 (en) 2000-04-05 2004-08-23 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
CZ20023473A3 (cs) 2000-04-19 2003-01-15 Schering Corporation Makrocyklická sloučenina a farmaceutický prostředek
EP1292310A1 (fr) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Nouveaux anti-infectieux
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
BR0112666A (pt) 2000-07-21 2003-06-10 Schering Corp Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
EP1256628A3 (fr) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (fr) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
EP1506000B9 (fr) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7157424B2 (en) 2003-04-02 2007-01-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004092203A2 (fr) 2003-04-10 2004-10-28 Boehringer Ingelheim International, Gmbh Procede de preparation de composes macrocycliques
CA2521835A1 (fr) 2003-04-10 2004-10-21 Boehringer Ingelheim International Gmbh Procede pour preparer des composes macrocycliques par reaction de metathese catalysee par complexe de ruthenium
ES2386161T3 (es) 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
CN1791599A (zh) 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
US7642235B2 (en) * 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CA2539575C (fr) 2003-11-20 2015-01-20 Boehringer Ingelheim International Gmbh Procede d'elimination de metaux de transition, notamment, a partir de produits de reaction de metathese
EP1699558B1 (fr) 2003-12-08 2009-03-11 Boehringer Ingelheim International GmbH Elimination de sous-produit de ruthenium par traitement fluidique supercritique
EP1730167B1 (fr) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Peptides macrocycliques actifs contre le virus de l'hepatite c
EP1711514B1 (fr) 2004-01-28 2008-12-03 Boehringer Ingelheim International GmbH Methode pour suppresser des metaux de transition dans des solutions de reaction contentant des complexes de metaux de transition
CA2556917C (fr) 2004-03-15 2013-07-09 Boehringer Ingelheim International, Gmbh Procede de preparation de composes macrocycliques
EP1794179A1 (fr) 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Réaction de métathèse cyclisante en milieu fluide supercritique
CA2577831A1 (fr) 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Procede de fabrication d'inhibiteurs de protease hcv macrocycliques

Also Published As

Publication number Publication date
BRPI0414571A (pt) 2006-11-07
ES2361997T3 (es) 2011-06-27
IL174403A0 (en) 2006-08-01
JP4704342B2 (ja) 2011-06-15
TW200521144A (en) 2005-07-01
EA200600498A1 (ru) 2006-10-27
JP2011006420A (ja) 2011-01-13
RS20060197A (en) 2008-09-29
CA2536182A1 (fr) 2005-03-31
ECSP066448A (es) 2006-09-18
EP1673385B1 (fr) 2011-03-02
AU2004274051A1 (en) 2005-03-31
WO2005028501A1 (fr) 2005-03-31
DE602004031645D1 (de) 2011-04-14
CA2536182C (fr) 2012-07-24
US20100028300A1 (en) 2010-02-04
AR045938A1 (es) 2005-11-16
US20050080005A1 (en) 2005-04-14
JP2007529411A (ja) 2007-10-25
CN1856502A (zh) 2006-11-01
UY28525A1 (es) 2005-04-29
EP1673385A4 (fr) 2006-10-04
ATE500264T1 (de) 2011-03-15
KR20060094083A (ko) 2006-08-28
MXPA06003141A (es) 2006-06-05
PE20050431A1 (es) 2005-07-19
US7642235B2 (en) 2010-01-05
EP1673385A1 (fr) 2006-06-28

Similar Documents

Publication Publication Date Title
NO20061767L (no) Makrosykliske peptider som er aktive mot hepatitt C virus
NO20043591L (no) Makrosykliske peptider aktive mot hepatitt C virus
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
WO2004014852A3 (fr) Iminothiazolidinones s'utilisant comme inhibiteurs de replication du vhc
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
GEP20115248B (en) Hcv ns3 protease inhibitors
WO2004101602A3 (fr) Analogues de peptides inhibiteurs de l'hepatite c
DK1719773T3 (da) Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
DE602005023015D1 (de) Indolderivate als viruzide
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
GEP20084560B (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
NO2013003I2 (no) Forbindelser som NS3-serinproteaseinhibitorer for hepatitt C-virus, farmasøytiske preparater og anvendelse av forbindelsene til fremstilling av et medikament
WO2004072243A3 (fr) Inhibiteurs macrocycliques de la serine protease de l'hepatite c
DE602005010607D1 (de) Zyklosporinanalog
WO2003051910A3 (fr) Inhibiteur de protease du virus de l'hepatite c
TH78149B (th) แมโครไซคลิกเปปไทด์ที่ออกฤทธิ์ต่อต้านไวรัสตับอักเสบชนิด c

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application